 | Issue navigator |
| |
Cancer Cell International publishes selected research, proceedings and collections of thematic reviews as supplements. All articles published in supplements are subject to peer review and are free to access online. The journal also publishes supplements containing meeting abstracts.
Contents of Volume 4 Suppl 1
Association for Immunotherapy of Cancer: Cancer Immunotherapy  2nd Annual Meeting Meeting abstracts - A single PDF containing all abstracts in this Supplement is available here.
from Association for Immunotherapy of Cancer: Cancer Immunotherapy 2nd Annual Meeting
Mainz, Germany. 6 7 May 2004
|
Oral presentation
Bispecific costimulatory molecules for activation of tumor-killing lymphocytes
R Weth, M Biburger, W Wels
Cancer Cell International 2004, 4(Suppl 1):S1 (1 July 2004)
[Abstract] [Full text] [PDF] [PubMed] [Related articles]
Oral presentation
Antibody-based immunoreceptors: the impact of signalling domain, binding affinity and costimulation
A Hombach, C Heuser, H Abken
Cancer Cell International 2004, 4(Suppl 1):S2 (1 July 2004)
[Abstract] [Full text] [PDF]
Oral presentation
Tolerability and efficacy of the trifunctional antibody removab® (anti-EpCAM x anti-CD3) in patients with malignant ascites due to ovarian cancer: Results of a phase I/II study
P Wimberger, A Burges, V Gorbounova, H Sommer, B Schmalfeldt, J Pfisterer, M Lichinitser, A Makhson, M Ströhlein, W Eiermann, M Biakhov, V Moiseenko, A du Bois, R Kimmig
Cancer Cell International 2004, 4(Suppl 1):S3 (1 July 2004)
[Abstract] [Full text] [PDF]
Oral presentation
HLA DR-directed bispecific single-chain Fv antibodies for lymphoma therapy
Y Wachter, J Brünke, S Schuster, K Barbin, M Peipp, T Valerius, M Gramatzki, G Fey, R Repp
Cancer Cell International 2004, 4(Suppl 1):S4 (1 July 2004)
[Abstract] [Full text] [PDF]
Oral presentation
Increased frequency of CTLA4+ TGF + CD4+ CD25+ T cells in peripheral blood of patients with chronic lymphatic leukemia and multiple myeloma
M Beyer, M Kochanek, M von Bergwelt-Baildon, A Popov, J Wolf, JL Schultze
Cancer Cell International 2004, 4(Suppl 1):S5 (1 July 2004)
[Abstract] [Full text] [PDF]
Oral presentation
MMP-7 inhibits CTL tumor cell interaction
S Gregor, V Alla, J Kuball, M Theobald, PR Galle, D Strand, S Strand
Cancer Cell International 2004, 4(Suppl 1):S6 (1 July 2004)
[Abstract] [Full text] [PDF]
Oral presentation
Genetically modified natural killer cells specifically recognizing the tumor-associated antigens ErbB2/HER2 and EpCAM
C Uherek, T Müller, T Tonn, B Uherek, H-G Klingemann, WS Wels
Cancer Cell International 2004, 4(Suppl 1):S7 (1 July 2004)
[Abstract] [Full text] [PDF] [1 comment]
Oral presentation
Rapid functional exhaustion and deletion of cytotoxic T lymphocytes following immunization with recombinant adenovirus
E Scandella, P Krebs, B Odermatt, B Ludewig
Cancer Cell International 2004, 4(Suppl 1):S8 (1 July 2004)
[Abstract] [Full text] [PDF]
Oral presentation
High frequency of functionally active Melan-A specific T cells in a patient with progressive immunoproteasome-deficient melanoma
N Meidenbauer, A Zippelius, MJ Pittet, M Laumer, S Vogl, J Heymann, M Rehli, B Seliger, S Schwarz, F-A Le Gal, PY Dietrich, R Andreesen, P Romero, A Mackensen
Cancer Cell International 2004, 4(Suppl 1):S9 (1 July 2004)
[Abstract] [Full text] [PDF]
Oral presentation
Adoptive T cell therapy using antigen-specific CD8+ T cells for the treatment of patients with metastatic melanoma: a phase I clinical study
N Meidenbauer, S Vogl, M Laumer, J Heymann, R Andreesen, A Mackensen
Cancer Cell International 2004, 4(Suppl 1):S10 (1 July 2004)
[Abstract] [Full text] [PDF]
Oral presentation
Large scale in vitro expansion of polyclonal human CD4+CD25high regulatory T cells
P Hoffmann, R Eder, LA Kunz-Schughart, R Andreesen, M Edinger
Cancer Cell International 2004, 4(Suppl 1):S11 (1 July 2004)
[Abstract] [Full text] [PDF]
Oral presentation
Reversible HLA multimers (streptamers) for isolation of human cytotoxic T lymphocytes functionally active against tumor- and virus-derived antigens
J Neudorfer, B Schmidt, K Huster, M Schiemann, T Schmidt, H Wagner, C Peschel, DH Busch, H Bernhard
Cancer Cell International 2004, 4(Suppl 1):S12 (1 July 2004)
[Abstract] [Full text] [PDF]
Oral presentation
Therapeutic efficacy of RAGE-1 and MAGE-9 peptide specific cytotoxic T cell clones in renal cell carcinoma
N Oehlrich, M Linnebacher, S Stevanovic, M Zoeller
Cancer Cell International 2004, 4(Suppl 1):S13 (1 July 2004)
[Abstract] [Full text] [PDF]
Oral presentation
The role of glycosylation as a modulator for signalling strength in T cells
B Hauptrock, J Kuball, R-H Voss, M Brkic, C Huber, M Theobald
Cancer Cell International 2004, 4(Suppl 1):S14 (1 July 2004)
[Abstract] [Full text] [PDF]
Oral presentation
Migration of dendritic cells to regional lymph nodes in a vaccination trial
A Riccobon, R Ridolfi, R Galassi, M Petrini, M Stefanelli, L Fiammenghi, G Giorgetti, A Moretti, L Ridolfi, G Fiorentini
Cancer Cell International 2004, 4(Suppl 1):S15 (1 July 2004)
[Abstract] [Full text] [PDF]
Oral presentation
Transitory response to vaccination with PSCA-/PSA-peptide loaded, autologous dendritic cells in patients with metastatic, hormone-refractory prostate cancer
AK Kaskel, R Zeiser, R Jochim, W Schultze-Seemann, CF Waller, H Veelken
Cancer Cell International 2004, 4(Suppl 1):S16 (1 July 2004)
[Abstract] [Full text] [PDF]
Oral presentation
Vaccination with WT1 induces high frequency memory and effector T cells in peripheral blood and bone marrow associated with complete remission of recurrent AML
A Letsch, C Scheibenbogen, AM Asemissen, V Mailänder, E Thiel, U Keilholz
Cancer Cell International 2004, 4(Suppl 1):S17 (1 July 2004)
[Abstract] [Full text] [PDF]
Oral presentation
LUD00-014: Phase I Study of recombinant vaccinia-NY-ESO-1 (rV-NY-ESO-1) and recombinant fowlpox-NY-ESO-1 (rF-NY-ESO-1) in patients with NY-ESO-1 or LAGE positive cancers
A Bender, J Karbach, A Neumann, M Biskamp, D Jäger, S Gnjatic, E Hoffman, LJ Old, A Knuth, E Jäger
Cancer Cell International 2004, 4(Suppl 1):S18 (1 July 2004)
[Abstract] [Full text] [PDF]
Oral presentation
Tumor vaccination after allogeneic bone marrow cell reconstitution of the non-myeloablatively conditioned tumor-bearing murine host
M Zöller
Cancer Cell International 2004, 4(Suppl 1):S19 (1 July 2004)
[Abstract] [Full text] [PDF]
Poster presentation
Limiting the risk of immunogenicity by identification and removal of T-cell epitopes (DeImmunisation )
K Hellendoorn, T Jones, J Watkins, M Baker, A Hamilton, F Carr
Cancer Cell International 2004, 4(Suppl 1):S20 (1 July 2004)
[Abstract] [Full text] [PDF]
| |
|   |
